Early Sarepta data impress

In case you missed it, new data showed that an experimental gene therapy from Sarepta Therapeutics improved the strength and function of three patients with a rare muscle-wasting disease called limb-girdle muscular dystrophy. Two of the patients were 13 — the age in which muscle deterioration tends to rapidly accelerate. When tested nine months after the one-time infusion, however, the teenagers showed varying degrees of improvements, STAT’s Adam Feuerstein writes.

It's welcome news for Sarepta, whose stock has fallen since the FDA rejected one of its Duchenne muscular dystrophy drugs this past August.